The cellular mechanisms by which adenosine evokes release of nitric oxide from rat aortic endothelium

J Physiol. 2006 Jan 1;570(Pt 1):85-96. doi: 10.1113/jphysiol.2005.099390. Epub 2005 Oct 20.

Abstract

Adenosine and nitric oxide (NO) are important local mediators of vasodilatation. The aim of this study was to elucidate the mechanisms underlying adenosine receptor-mediated NO release from the endothelium. In studies on freshly excised rat aorta, second-messenger systems were pharmacologically modulated by appropriate antagonists while a NO-sensitive electrode was used to measure adenosine-evoked NO release from the endothelium. We showed that A1-mediated NO release requires extracellular Ca2+, phospholipase A2 (PLA2) and ATP-sensitive K+ (KATP) channel activation whereas A2A-mediated NO release requires extracellular Ca2+ and Ca2+-activated K+ (KCa) channels. Since our previous study showed that A1- and A2A-receptor-mediated NO release requires activation of adenylate cyclase (AC), we propose the following novel pathways. The K+ efflux resulting from A1-receptor-coupled KATP-channel activation facilitates Ca2+ influx which may cause some stimulation of endothelial NO synthase (eNOS). However, the increase in [Ca2+]i also stimulates PLA2 to liberate arachidonic acid and stimulate cyclooxygenase to generate prostacyclin (PGI2). PGI2 acts on its endothelial receptors to increase cAMP, so activating protein kinase A (PKA) to phosphorylate and activate eNOS resulting in NO release. By contrast, the K+ efflux resulting from A2A-coupled KCa channels facilitates Ca2+ influx, thereby activating eNOS and NO release. This process may be facilitated by phosphorylation of eNOS by PKA via the action of A2A-receptor-mediated stimulation of AC increasing cAMP. These pathways may be important in mediating vasodilatation during exercise and systemic hypoxia when adenosine acting in an endothelium- and NO-dependent manner has been shown to be important.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine / pharmacology*
  • Animals
  • Aorta, Thoracic / drug effects
  • Aorta, Thoracic / metabolism
  • Apamin / pharmacology
  • Arachidonic Acids / pharmacology
  • Calcium / metabolism
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / metabolism
  • In Vitro Techniques
  • Large-Conductance Calcium-Activated Potassium Channels / drug effects
  • Male
  • Nitric Oxide / metabolism
  • Peptides / pharmacology
  • Phospholipases A / drug effects
  • Phospholipases A2
  • Rats
  • Rats, Wistar
  • Receptor, Adenosine A1 / drug effects
  • Receptors, Adenosine A2 / drug effects
  • Second Messenger Systems / drug effects
  • Small-Conductance Calcium-Activated Potassium Channels / drug effects
  • Triazines / pharmacology
  • Triazoles / pharmacology
  • Vasodilator Agents / pharmacology*
  • Xanthines / pharmacology

Substances

  • Arachidonic Acids
  • Large-Conductance Calcium-Activated Potassium Channels
  • Peptides
  • Receptor, Adenosine A1
  • Receptors, Adenosine A2
  • Small-Conductance Calcium-Activated Potassium Channels
  • Triazines
  • Triazoles
  • Vasodilator Agents
  • Xanthines
  • ZM 241385
  • arachidonyltrifluoromethane
  • Apamin
  • Nitric Oxide
  • iberiotoxin
  • 1,3-dipropyl-8-cyclopentylxanthine
  • Phospholipases A
  • Phospholipases A2
  • Adenosine
  • Calcium